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Abstract
Background: This meta-analytic study explored the relationship between the risk of type 2 diabetes mellitus
(T2DM) and bisphenol A concentrations.
Methods: The Embase and Medline (PubMed) databases were searched, using relevant keywords, for studies
published between 1980 and 2018. A total of 16 studies, twelve cross-sectional, two case-control and one
prospective, were included in the meta-analysis. The odds ratio (OR) and its 95% confidence interval (CI) were
determined across the sixteen studies. The OR and its 95% CI of diabetes associated with bisphenol A were
estimated using both fixed-effects and random-effects models.
Results: A total of 41,320 subjects were included. Fourteen of the sixteen studies included in the analysis provided
measurements of urine bisphenol A levels and two study provided serum bisphenol A levels. Bisphenol A concentrations
in human bio-specimens showed positive associations with T2DM risk (OR 1.28, 95% CI 1.14, 1.44). A sensitivity analysis
indicated that urine bisphenol A concentrations were positively associated with T2DM risk (OR 1.20, 95% CI 1.09, 1.31).
Conclusions: This meta-analysis indicated that Bisphenol A exposure is positively associated with T2DM risk in humans.
Keywords: Bisphenol a (BPA), Endocrine disrupting chemicals (EDCs), Diabetes mellitus (DM), Type 2 diabetes mellitus
(T2DM), Hemoglobin A1c (HbA1c), Fasting plasma glucose, Obesity, Meta-analysis
Background
Type 2 diabetes mellitus (T2DM) is a metabolic disease
that presents with symptoms of insulin resistance and
lack of insulin [1]. The global prevalence of T2DM
among adults is about 415million, but based on projec-
tions by the International Federation of Diabetes is ex-
pected to reach 642 million in 2040 [2, 3].
Bisphenol A (BPA) is a role for endocrine disrupting
chemicals (EDCs) and especially used in epoxy resin and
polycarbonate plastic products such as food packaging,
drink containers, and dental sealants [4–7]. Once the
EDCs is deposited in the body, they can interfere with the
physiological effects of estrogen, androgen and thyroid
hormones by functioning as a hormone agonists and an-
tagonists. Especially, BPA or EDCs interfere with cell sig-
nal pathways related to weight and glucose homeostasis.
A number of previous experimental and epidemiological
studies have found that EDCs can penetrate the body in
several ways, including dietary intake, inhalation, skin con-
tact, and other pathways. Thus, EDCs may have been as-
sociated with mainly the occurrence of hormone-like
effects disorders and even cancers [7].
Competitive with 17- beta estradiol (E2), BPA is a type
of endocrine disrupting chemical (EDCs) that disrupts
estrogenic response by binding to estrogen receptors.
BPA binds to androgen receptors and thyroid receptors.
Unfortunately, humans are exposed to BPA through the
daily exposure to BPA containing products such as
canned food, plastic products, dental sealants, and
household dust [7, 8].
In recent studies, research findings suggest that low
levels of BPA can cause significant health problems. A
number of scientists hypothesized that adverse health ef-
fects might be associated with high urinary BPA concen-
trations. Epidemiological studies have been carried out
to evaluate the possible association between BPA expos-
ure and the risk of T2DM, but the results were not con-
sistent [9–24].
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In this study, a meta-analysis focusing on the associ-
ation between BPA concentrations (measured in urine
or serum) and the risk of T2DM was performed. In
addition, subgroup analyses were performed according
to the sample type (urine or serum) and the study
design.
Methods
Study selection
Figure 1 shows a PRISMA flow diagram that describes the
selection process of this meta-analysis (Additional file 1:
Table S1). As shown in the figure, the Embase and Med-
line (PubMed) databases were searched between 1980 and
2018 using Medical Subject Headings (MeSH) terms re-
lated to BPA and diabetes.
The keywords used in the Embase and Medline
(PubMed) database searches were: Bisphenol A, BPA, 4,
4 isopropylidenediphenol or Bisphenol A bis (2 hydroxy-
propyl) ether dimethacrylate and Noninsulin dependent
diabetes mellitus or Type 2 diabetes or Diabetes Melli-
tus, Type 2 or Diabetes Mellitus, Noninsulin-Dependent
or Diabetes Mellitus, Ketosis-Resistant or Diabetes
Mellitus, Fasting blood sugar or Fasting plasma glucose
or Blood glucose, HbA1c or Glycosylated hemoglobin or
Hemoglobin A1cor Glycated Hemoglobin A or
Hemoglobin A, Glycated. A total of 420 articles were
found: 246 were from Embase and 174 were from
Medline (PubMed). First, 139 duplicated articles were
removed., After, an initial review, 148 studies were ex-
cluded; 85 studies were not human research such as ani-
mal and invitro experiment, 43 studies had irrelevant
exposures or outcomes and 20 studies were reviews or
meta-analyses papers. Next, 133 studies were selected
for full-text article review. From these studies, 117 stud-
ies, including 44 studies were not human research, 38
with irrelevant exposures or outcomes, 10 studies were
reviews or meta-analyses, 22 were letter or book or com-
ment papers, and 3 had not find full text from the same
database were excluded. Finally, a total of 16 articles
were included in this meta-analysis (Fig. 1).
Data extraction
Data extraction was completed twice by two reviewers,
Hwang, S. and Lim, J.E. independently, with no disagree-
ment in the selection of the final sixteen articles [9–24].
The reviewers selected the variables while considering
authors, year of publication, country, type of study, type
of sample, unit of measurement, population, comparison
categories, and adjusted odds ratios (OR) with corre-
sponding confidence intervals, and model adjustments.
To be included in the meta-analysis, a published study
had to be the original article published between 1980
and 2018. A total of 16 studies published between Sep-
tember, 2008 and January, 2018 were selected for final
inclusion. We conducted quality assessment using the
Fig. 1 A PRISMA flow diagram
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Downs and Black score [25]. The average quality score
was 16 with scores ranging from 13 to 18.
Statistical analyses
Odds ratios (OR) and 95% confidence intervals (95% CI)
were obtained from the selected articles using the stand-
ard guidelines for meta-analysis [26]. Fixed-effects model
and random-effects model were implemented. Hetero-
geneity was tested using the Cochrane Q-test and I2 stat-
istic, considering an I2 value > 50% as indicative of
substantial heterogeneity. A study with a significantly high
OR was omitted from the meta-analysis to avoid overrep-
resentation. Analyses were performed by sub-groups: type
of sample (serum or urine), and type of study (cross-sec-
tional, case-control and prospective) as possible sources of
heterogeneity. A Begg’s Funnel Plot and an Egger’s Regres-
sion Test were conducted to minimize publication bias
and asymmetry of the studies. When publication bias ex-
ists, the Begg’s Funnel Plot is asymmetric, or the Egger’s
Test P-value < 0.05 [27].
To adjust for the cross-study differences between the
BPA concentration units and the range of measured
values, a dose-response meta-analysis (DRMA) was imple-
mented. The dose-response meta-analyses (DRMA) was
implemented by using the STATA GLST command [28]
on a sample off our studies (Additional file 2: Figure S2).
Statistical analyses were performed using STATA ver-
sion 13.0 software (Stata Corp, College Station, Texas).
Results
The 420 studies were searched using a systematic search
strategy, referring to the PRISMA flow chart that de-
scribes the selection process of the meta-analysis [29].
After the duplicate records were removed, each article
was reviewed by title, abstract, and full-text. Sixteen
studies, 12 cross-sectional, 3 case-control and 1 pro-
spective studies remained. A total of 6855 diabetic pa-
tients from among 141,320 subjects were included in the
study.
Table 1 represents the characteristics of the studies in-
cluded in the meta-analysis. The selected studies were
performed in the USA, Korea, Iran, China and Thailand.
While using funnel plot asymmetry to detect publication
bias and applying Egger’s regression test to measure for
asymmetry, a very low publication bias was confirmed .
BPA exposure was positively associated with the risk
of T2DM (Fig. 2). The pooled OR of the random-effects
model was 1.28 (95% CI, 1.14–1.44). Figure 3 presents
the forest plot of sensitivity analysis after three studies
were excluded, one for exhibiting highly heterogeneous
results (OR 57.60; 95% CI 21.10–157.05) [20] and two
for using serum BPA concentrations [22, 24].
In Fig. 4 and Additional file 2: Figure S2, the funnel
plot shows publication bias in the meta-analysis. Of the
studies used in 16 final meta-analysis, only five were
found to have no bias, four using urine BPA and one
with serum BPA.
Discussion
In this meta-analysis, we observed that the exposure of
BPA was associated with an increased risk of T2DM.
Both urine and serum BPA levels were positively associ-
ated with the risk of T2DM. The results of this study
showed pooled OR of 1.28 (95% CI 1.14–1.44).
Previous studies have identified that the association be-
tween urinary BPA levels and T2DM may be biologically
feasible. For example, BPA, an estrogen agonist that acts
as an endocrine hormone disruptor, has been shown to be
involved in several mechanisms of diabetes development
including glucose homeostasis, obesity, insulin resistance,
beta-cell dysfunction, inflammation, and oxidative stress
[30]. BPA binding to estrogen receptors (ER) at concentra-
tions at the physiological range or below can disrupt the
pancreatic islets of Langherans, which are an essential tis-
sue responsible for glucose metabolism [31]. BPA binding
to pancreatic islet cells can induce impaired insulin or glu-
cagon secretion, leading to an insulin-resistant state. In
animal studies, adult mice exposed to low-dose BPA dis-
played both hyperinsulinemia and insulin resistance that
are associated with pancreatic beta-cell dysfunction [32].
BPA can also act on peripheral insulin-sensitive tissues
like muscle, liver, and adipose tissue [31]. Several in-vivo
studies reported that BPA exposed mice showed decreased
levels of circulating adiponectin as well as dysregulation of
insulin signaling in skeletal muscle and liver. The mice
also showed increased levels of pro-inflammatory cyto-
kines, such as interleukin-6 and tumor necrosis factors,
which favor the development of insulin resistance [33].
Additionally, BPA has an obesogen effect resulting in the
development of obesity and metabolic disorders. Sheep
exposed to BPA during the prenatal period became over-
weight, experienced an increase in adipocyte mass, and in
insulin resistance [34–36]. The induction by BPA of the
insulin resistance that precedes T2DM is mainly seen
when humans and animals are in a rapid growth phase.
Some studies have shown that BPA exposure during preg-
nancy or childhood causes metabolic disorders in both
humans and animals [37, 38]. However, further studies are
needed to clarify the complete mechanisms of BPA expos-
ure and T2DM risk.
Previous meta-analyses, have not implemented the
dose-response analytic method used in this study to deter-
mine the relationship between BPA exposure and the risk
of T2DM. A significant dose-response relationship was
found between urinary BPA concentrations (mg/dL) and
T2DM risk. In addition, subgroup analysis was performed
according to the type of sample (urine or serum), and the
type of study (cross-sectional, case-control and prospective
Hwang et al. BMC Endocrine Disorders           (2018) 18:81 Page 3 of 10
Ta
b
le
1
Ri
sk
es
tim
at
es
an
d
st
ud
y
in
fo
rm
at
io
n
fro
m
ab
st
ra
ct
s
of
or
ig
in
al
st
ud
ie
s
on
BP
A
co
nc
en
tr
at
io
n
an
d
ty
pe
2
di
ab
et
es
m
el
lit
us
Re
fe
re
nc
e
C
ou
nt
ry
Ty
pe
of st
ud
y
U
se
d
sa
m
pl
e
U
ni
t
Po
pu
la
tio
n
(C
as
e
/
To
ta
l)
C
om
pa
ris
on
ca
te
go
rie
s
A
dj
us
te
d
O
R
95
%
C
I
A
dj
us
tm
en
t
in
m
od
el
Q
ua
lit
y
sc
or
e
La
ng
et
al
.
(2
00
8)
[9
]
Th
e
U
ni
te
d
St
at
es
C
ro
ss
-
se
ct
io
na
l
U
rin
e
ng
/m
L
13
6
/
14
55
BP
A
co
nt
in
uo
us
1.
39
1.
21
–1
.6
0
A
ge
,s
ex
,r
ac
e/
et
hn
ic
ity
,e
du
ca
tio
n,
in
co
m
e,
sm
ok
in
g,
BM
I,
w
ai
st
ci
rc
um
fe
re
nc
e
an
d
ur
in
ar
y
cr
ea
tin
in
e
co
nc
en
tr
at
io
ns
,
17
M
el
ze
r
et
al
.
(2
01
0)
[1
0]
Th
e
U
ni
te
d
St
at
es
C
ro
ss
-
se
ct
io
na
l
U
rin
e
ng
/m
L
27
7
/
29
47
BP
A
co
nt
in
uo
us
1.
24
1.
10
–1
.4
0
A
ge
,s
ex
,r
ac
e/
et
hn
ic
ity
,e
du
ca
tio
n,
in
co
m
e,
sm
ok
in
g,
BM
I,
w
ai
st
ci
rc
um
fe
re
nc
e,
an
d
ur
in
ar
y
cr
ea
tin
in
e
co
nc
en
tr
at
io
n.
18
Si
lv
er
et
al
.
(2
01
1)
[1
1]
Th
e
U
ni
te
d
St
at
es
C
ro
ss
-
se
ct
io
na
l
U
rin
e
ng
/m
L
54
0
/
43
89
BP
A
co
nt
in
uo
us
1.
08
1.
02
–1
.1
6
A
ge
,a
ge
2 ,
ur
in
ar
y
cr
ea
tin
in
e
as
na
tu
ra
ls
pl
in
es
(re
st
ric
te
d
cu
bi
c
sp
lin
es
)
w
ith
4
de
gr
ee
s
of
fre
ed
om
(k
no
ts
at
25
th
,5
0t
h,
an
d
75
th
pe
rc
en
til
es
),
BM
I,
w
ai
st
ci
rc
um
fe
re
nc
e,
an
d
sm
ok
in
g
st
at
us
.
17
N
in
g
et
al
.
(2
01
1)
[1
2]
Th
e
U
ni
te
d
St
at
es
C
ro
ss
-
se
ct
io
na
l
U
rin
e
ng
/m
L
10
87
/
34
23
BP
A
in
qu
ar
til
es
Q
1:
≤
0.
47
,
Q
2:
0.
48
–0
.8
1,
Q
3:
0.
82
–1
.4
3,
Q
4:
>
1.
43
1.
37
1.
08
−
1.
74
A
ge
,s
ex
,e
du
ca
tio
na
ll
ev
el
,f
am
ily
hi
st
or
y
of
di
ab
et
es
,W
C,
sy
st
ol
ic
bl
oo
d
pr
es
su
re
,l
n(
TG
le
ve
l),
ln
(h
sC
RP
le
ve
l),
ln
(A
LT
le
ve
l),
es
tim
at
ed
gl
om
er
ul
ar
fil
tr
at
io
n
ra
te
,a
lb
um
in
le
ve
l
an
d
to
ta
lb
ili
ru
bi
n
le
ve
l.
15
Sh
an
ke
r
&
Te
pp
al
a
(2
01
1)
[1
3]
Th
e
U
ni
te
d
St
at
es
C
ro
ss
-
se
ct
io
na
l
U
rin
e
ng
/m
L
46
7
/
39
67
BP
A
in
qu
ar
til
es
Q
1:
<
1.
10
,
Q
2:
1.
10
–2
.1
0,
Q
3:
2.
11
–4
.2
0,
Q
4:
>
4.
20
1.
68
1.
22
–2
.3
0
A
ge
(y
ea
rs
),
ge
nd
er
,r
ac
e-
et
hn
ic
ity
(n
on
-H
is
pa
ni
c
w
hi
te
s,
no
n-
H
is
pa
ni
c
bl
ac
ks
,M
ex
ic
an
-A
m
er
ic
an
s,
ot
he
rs
),
ed
uc
at
io
n
ca
te
go
rie
s
(b
el
ow
hi
gh
sc
ho
ol
,
hi
gh
sc
ho
ol
,a
bo
ve
hi
gh
sc
ho
ol
),
sm
ok
in
g
(n
ev
er
,
fo
rm
er
,c
ur
re
nt
),
al
co
ho
li
nt
ak
e
(n
ev
er
,f
or
m
er
,c
ur
re
nt
),
BM
I(
no
rm
al
,o
ve
rw
ei
gh
t,
ob
es
e)
,s
ys
to
lic
an
d
di
as
to
lic
bl
oo
d
pr
es
su
re
(m
m
H
g)
,u
rin
ar
y
cr
ea
tin
in
e
(m
g/
dl
),
an
d
to
ta
lc
ho
le
st
er
ol
(m
g/
dl
).
16
W
an
g
et
al
.
(2
01
1)
[1
4]
C
hi
na
C
ro
ss
-
se
ct
io
na
l
U
rin
e
ng
/m
L
10
48
/
33
90
BP
A
in
qu
ar
til
es
Q
1:
≤
0.
47
,
Q
2:
0.
48
–0
.8
1,
Q
3:
0.
82
–1
.4
3,
Q
4:
>
1.
43
1.
37
1.
06
–1
.7
7
A
ge
,s
ex
,B
M
I,
ur
in
ar
y
cr
ea
tin
in
e
co
nc
en
tr
at
io
n,
sm
ok
in
g,
al
co
ho
ld
rin
ki
ng
,e
du
ca
tio
n
le
ve
ls
,
sy
st
ol
ic
bl
oo
d
pr
es
su
re
,H
D
L-
C
,L
D
L-
C
,T
C
,T
G
,
hs
-C
RP
,f
as
tin
g
pl
as
m
a
gl
uc
os
e,
fa
st
in
g
se
ru
m
in
su
lin
,a
nd
se
ru
m
A
LT
an
d
G
G
T.
17
La
Ki
nd
et
al
.
(2
01
2)
[1
5]
Th
e
U
ni
te
d
St
at
es
C
ro
ss
-
se
ct
io
na
l
U
rin
e
ng
/m
L
48
23
BP
A
co
nt
in
uo
us
0.
99
5
0.
98
2–
1.
00
7
C
re
at
in
in
e,
ag
e,
ge
nd
er
,e
th
ni
ci
ty
,e
du
ca
tio
n,
in
co
m
e,
sm
ok
in
g,
dr
in
ki
ng
,B
M
I,
w
ai
st
ci
rc
um
fe
re
nc
e,
hy
pe
rt
en
si
on
,t
ot
al
ch
ol
es
te
ro
la
nd
fa
m
ily
hi
st
or
y.
15
Ki
m
&
Pa
rk
(2
01
3)
[1
6]
Ko
re
a
C
ro
ss
-
se
ct
io
na
l
U
rin
e
ng
/m
L
99
/
12
10
BP
A
in
qu
ar
til
es
Q
1:
<
1.
36
,
Q
2:
1.
36
–2
.1
4
Q
3:
2.
15
–3
.3
2,
Q
4:
>
3.
32
1.
71
0.
89
−
3.
26
C
re
at
in
in
e,
ag
e,
se
x,
BM
I,
ed
uc
at
io
n,
sm
ok
in
g,
in
co
m
e
an
d
pl
ac
e
of
re
si
de
nc
e.
17
Hwang et al. BMC Endocrine Disorders           (2018) 18:81 Page 4 of 10
Ta
b
le
1
Ri
sk
es
tim
at
es
an
d
st
ud
y
in
fo
rm
at
io
n
fro
m
ab
st
ra
ct
s
of
or
ig
in
al
st
ud
ie
s
on
BP
A
co
nc
en
tr
at
io
n
an
d
ty
pe
2
di
ab
et
es
m
el
lit
us
(C
on
tin
ue
d)
Re
fe
re
nc
e
C
ou
nt
ry
Ty
pe
of st
ud
y
U
se
d
sa
m
pl
e
U
ni
t
Po
pu
la
tio
n
(C
as
e
/
To
ta
l)
C
om
pa
ris
on
ca
te
go
rie
s
A
dj
us
te
d
O
R
95
%
C
I
A
dj
us
tm
en
t
in
m
od
el
Q
ua
lit
y
sc
or
e
Sa
ba
na
ya
ga
m
et
al
.(
20
13
)
[1
7]
Th
e
U
ni
te
d
St
at
es
C
ro
ss
-
se
ct
io
na
l
U
rin
e
ng
/m
L
11
08
/
35
16
BP
A
in
te
rt
ile
s
Q
1:
<
1.
3,
Q
2:
1.
3–
3.
2,
Q
3:
>
3.
2
1.
34
1.
03
–1
.7
3
A
ge
(y
ea
rs
),
ge
nd
er
(m
al
e,
fe
m
al
e)
,r
ac
e-
et
hn
ic
ity
(n
on
-H
is
pa
ni
c
w
hi
te
s,
no
n-
H
is
pa
ni
c
bl
ac
ks
,M
ex
ic
an
A
m
er
ic
an
s,
ot
he
rs
),
ed
uc
at
io
n
ca
te
go
rie
s
(b
el
ow
hi
gh
sc
ho
ol
,h
ig
h
sc
ho
ol
,
ab
ov
e
hi
gh
sc
ho
ol
),
sm
ok
in
g
(n
ev
er
,f
or
m
er
,
cu
rr
en
t)
,a
lc
oh
ol
in
ta
ke
(n
ev
er
,f
or
m
er
,
cu
rr
en
t)
,b
od
y
m
as
s
in
de
x
(n
or
m
al
,
ov
er
w
ei
gh
t,
ob
es
e)
,p
hy
si
ca
li
na
ct
iv
ity
(a
bs
en
t,
pr
es
en
t)
,m
ea
n
ar
te
ria
lb
lo
od
pr
es
su
re
(m
m
of
H
g)
,C
-r
ea
ct
iv
e
pr
ot
ei
n
an
d
to
ta
lc
ho
le
st
er
ol
/H
D
L
ra
tio
13
C
as
ey
&
N
ei
de
ll
et
al
.(
20
13
)
[1
8]
Th
e
U
ni
te
d
St
at
es
C
ro
ss
-
se
ct
io
na
l
U
rin
e
ng
/m
L
48
7
/
46
58
BP
A
co
nt
in
uo
us
1.
06
5
0.
97
3–
1.
16
6
A
ge
,s
ex
,u
rin
ar
y
cr
ea
tin
in
e
co
nc
en
tr
at
io
n,
ra
ce
/e
th
ni
ci
ty
,i
nc
om
e,
sm
ok
in
g,
BM
I,
w
ai
st
ci
rc
um
fe
re
nc
e,
ve
te
ra
n/
m
ili
ta
ry
st
at
us
,
ci
tiz
en
sh
ip
st
at
us
,m
ar
ita
ls
ta
tu
s,
ho
us
eh
ol
d
si
ze
,p
re
gn
an
cy
st
at
us
,l
an
gu
ag
e
at
su
bj
ec
t
in
te
rv
ie
w
,h
ea
lth
in
su
ra
nc
e
co
ve
ra
ge
,
em
pl
oy
m
en
t
st
at
us
in
th
e
pr
io
r
w
ee
k,
co
ns
um
pt
io
n
of
bo
tt
le
d
w
at
er
in
th
e
pa
st
24
h,
co
ns
um
pt
io
n
of
al
co
ho
l,
an
nu
al
co
ns
um
pt
io
n
of
tu
na
fis
h,
pr
es
en
ce
of
em
ot
io
na
ls
up
po
rt
in
on
e’
s
lif
e,
be
in
g
on
a
di
et
,u
si
ng
a
w
at
er
tr
ea
tm
en
t
de
vi
ce
,
ac
ce
ss
to
a
ro
ut
in
e
so
ur
ce
of
he
al
th
ca
re
,
va
cc
in
at
ed
fo
r
H
ep
at
iti
s
A
or
B,
co
ns
um
pt
io
n
of
di
et
ar
y
su
pp
le
m
en
ts
(v
ita
m
in
s
or
m
in
er
al
s)
,
an
d
in
ab
ili
ty
to
pu
rc
ha
se
ba
la
nc
ed
m
ea
ls
on
a
co
ns
is
te
nt
ba
si
s.
16
Su
n
et
al
.
(2
01
4)
[1
9]
Th
e
U
ni
te
d
St
at
es
(N
H
S)
C
as
e-
co
nt
ro
l
U
rin
e
μg
/L
39
4
/
78
7
BP
A
in
qu
ar
til
es
Q
1:
<
1.
0,
Q
2:
1.
0–
1.
5,
Q
3:
1.
5–
2.
7,
Q
4:
>
2.
7
0.
98
0.
6–
1.
61
A
ge
,e
th
ni
ci
ty
,f
as
tin
g
st
at
us
,
tim
e
of
sa
m
pl
e
co
lle
ct
io
n,
m
en
op
au
sa
ls
ta
tu
s,
us
e
of
ho
rm
on
e
re
pl
ac
em
en
t
th
er
ap
y
(N
H
SI
I),
ur
in
ar
y
cr
ea
tin
in
e
le
ve
ls
,s
m
ok
in
g,
po
st
m
en
op
au
sa
lh
or
m
on
e
us
e
(N
H
S)
,o
ra
l
co
nt
ra
ce
pt
iv
e
us
e
(N
H
SI
I),
ph
ys
ic
al
ac
tiv
ity
,
dr
in
ki
ng
,f
am
ily
hi
st
or
y
of
di
ab
et
es
,h
is
to
ry
of
hy
pe
rc
ho
le
st
er
ol
em
ia
or
hy
pe
rt
en
si
on
,
A
lte
rn
at
iv
e
H
ea
lth
Ea
tin
g
In
de
x
sc
or
e,
BM
I
15
Th
e
U
ni
te
d
St
at
es
(N
H
S
II)
C
as
e-
co
nt
ro
l
U
rin
e
μg
/L
57
7
/
11
54
BP
A
in
qu
ar
til
es
Q
1:
<
1.
0,
Q
2:
1.
0–
1.
5,
Q
3:
1.
5–
2.
7,
Q
4:
>
2.
7
2.
08
1.
17
−
3.
69
A
hm
ad
kh
an
ih
a
et
al
.(
20
14
)
[2
0]
Ira
n
C
as
e-
co
nt
ro
l
U
rin
e
μg
/L
11
9
/
23
9
BP
A
in
tw
o
gr
ou
ps
ba
se
d
on
th
e
m
ed
ia
n
(<
0.
85
an
d
≥
0.
85
μg
/L
)
57
.6
21
.1
−
15
7.
05
A
ge
,s
ex
,B
M
I,
hy
pe
rt
en
si
on
,s
er
um
tr
ig
ly
ce
rid
e
le
ve
l,
se
ru
m
ch
ol
es
te
ro
ll
ev
el
,s
er
um
cr
ea
tin
in
e
(s
m
ok
in
g
an
d
co
ns
um
pt
io
n
of
su
ga
re
d
dr
in
ks
in
pl
as
tic
bo
tt
le
s
or
ca
nn
ed
fo
od
in
tw
o
pa
st
w
ee
ks
w
er
e
ex
cl
us
io
n
cr
ite
ria
)
15
A
nd
ra
S.
S.
et
al
.
(2
01
5)
[2
1]
Th
e
U
ni
te
d
St
at
es
C
ro
ss
-
se
ct
io
na
l
U
rin
e
ng
/m
L
20
/
13
1
BP
A
co
nt
in
uo
us
0.
77
0.
24
–2
.0
4
A
ge
,s
ex
,B
M
I,
fa
st
in
g
st
at
us
,s
m
ok
in
g,
al
co
ho
l
us
e,
ph
ys
ic
al
ac
tiv
ity
an
d
fa
m
ily
hi
st
or
y
18
Hwang et al. BMC Endocrine Disorders           (2018) 18:81 Page 5 of 10
Ta
b
le
1
Ri
sk
es
tim
at
es
an
d
st
ud
y
in
fo
rm
at
io
n
fro
m
ab
st
ra
ct
s
of
or
ig
in
al
st
ud
ie
s
on
BP
A
co
nc
en
tr
at
io
n
an
d
ty
pe
2
di
ab
et
es
m
el
lit
us
(C
on
tin
ue
d)
Re
fe
re
nc
e
C
ou
nt
ry
Ty
pe
of st
ud
y
U
se
d
sa
m
pl
e
U
ni
t
Po
pu
la
tio
n
(C
as
e
/
To
ta
l)
C
om
pa
ris
on
ca
te
go
rie
s
A
dj
us
te
d
O
R
95
%
C
I
A
dj
us
tm
en
t
in
m
od
el
Q
ua
lit
y
sc
or
e
A
ek
pl
ak
or
n
W
et
al
.(
20
15
)
[2
2]
Th
e
Th
ai
la
nd
C
ro
ss
-
se
ct
io
na
l
Se
ru
m
ng
/m
L
23
/
25
58
BP
A
in
qu
ar
til
es
Q
1:
<
1.
0,
Q
2:
1.
0–
2.
0,
Q
3:
2.
0–
3.
7,
Q
4:
>
3.
7
1.
88
1.
18
–2
.9
9
A
ge
,s
ex
,u
rin
ar
y
cr
ea
tin
in
e,
ra
ce
,e
du
ca
tio
n,
sm
ok
in
g,
ph
ys
ic
al
ac
tiv
ity
,d
ie
ta
ry
en
er
gy
in
ta
ke
an
d
su
rv
ey
w
av
e
17
Bi
Y.
et
al
.
(2
01
6)
[2
3]
C
hi
na
pr
os
pe
ct
iv
e
U
rin
e
ng
/m
L
24
1
/
22
09
BP
A
in
qu
ar
til
es
0.
78
0.
53
–1
.1
6
A
ge
,s
ex
,f
am
ily
hi
st
or
y
of
di
ab
et
es
,B
M
I(
fo
r
w
ei
gh
te
d
G
RS
),
an
d
fu
rt
he
r
fo
r
sm
ok
in
g
st
at
us
,s
ys
to
lic
bl
oo
d
pr
es
su
re
,d
ia
st
ol
ic
bl
oo
d
pr
es
su
re
,l
g
(t
ot
al
ch
ol
es
te
ro
l),
lg
(t
rig
ly
ce
rid
es
),
fa
st
in
g
pl
as
m
a
gl
uc
os
e,
an
d
lg
(u
rin
ar
y
cr
ea
tin
in
e)
fo
r
BP
A
.
16
Sh
u
et
al
.
(2
01
8)
[2
4]
C
hi
na
C
as
e-
co
nt
ro
l
Se
ru
m
ng
/m
L
23
2
/
46
4
BP
A
in
te
rt
ile
s
0.
93
0.
41
–2
.1
3
A
ge
,s
ex
,B
M
I,
ex
er
ci
se
,c
ur
re
nt
sm
ok
in
g,
sy
st
ol
ic
bl
oo
d
pr
es
su
re
,d
ia
st
ol
ic
bl
oo
d
pr
es
su
re
,f
as
tin
g
pl
as
m
a
gl
uc
os
e,
2-
h
pl
as
m
a
gl
uc
os
e
in
or
al
gl
uc
os
e
to
le
ra
nc
e
te
st
,t
ot
al
ch
ol
es
te
ro
l,
tr
ig
ly
ce
rid
e,
hi
gh
-d
en
si
ty
lip
op
ro
te
in
ch
ol
es
te
ro
la
nd
lo
w
-d
en
si
ty
lip
op
ro
te
in
ch
ol
es
te
ro
l.
15
Hwang et al. BMC Endocrine Disorders           (2018) 18:81 Page 6 of 10
Fig. 3 Forest plot after exclusion of studies with serum BPA levels and high heterogeneity
Fig. 2 Forest plot according to sample type
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study). Moreover, quality assessment methods were imple-
mented to remove any irrelevant studies and to improve
the validity of the meta-analysis. The current study consid-
ered only diabetes as a primary outcome variable as was
the case with the final sixteen articles used for the
meta-analysis. Despite the fact that diabetes mellitus is an
important risk factor for cardiovascular disease, our study
will focus specifically on T2DM, and as a result will be
more focused and statistically significant than previous
studies.
There were several limitations to the conduct and ana-
lysis in this study that must be considered. First, because
of the limited number of cohort studies investigating the
relationship between BPA exposure and T2DM risk that
have been conducted, this meta-analysis included only
thirteen cross-sectional, two case-control studies and
one prospective studies. The inclusion of additional
studies are required to validate and confirm these re-
sults. Second, this meta-analysis included fourteen stud-
ies which used spot urinary BPA concentrations and two
study that used serum BPA concentrations as a surro-
gate marker of BPA exposure. It is unclear whether spot
urinary BPA concentrations could accurately reflect the
long term exposure level of BPA in individuals. Spot
urinary BPA concentrations are the most commonly
used method to assess BPA exposure levels because of it
is short half-life and the convenience of the measure-
ment method [11, 20]. Although some studies have dem-
onstrated that spot urine samples can reasonably predict
long-term exposures in adults [39, 40], the validity of
such results still needs to be proven. Some recent epi-
demiological studies used serum BPA concentrations to
investigate the health effects of BPA [22, 40]. In these
studies, the authors explained that serum BPA could be
an appropriate surrogate for BPA exposure because
serum BPA reflected the true levels of active BPA [22].
There is not sufficient information to determine the
most suitable method for measuring BPA concentrations
(e.g. spot urinary BPA concentrations, 24-h urinary BPA
concentrations, serum BPA concentration) that accur-
ately reflect the level of BPA exposure. Third, although
linear relationships between BPA exposure and risk of
T2DM were tested in this meta-analysis, several studies
have suggested inverted U-shape or non-linear relation-
ships [19, 21, 22]. To clarify this complex dose–response
relationship, more detailed research is required. Fourth,
a random effects model was implemented after perform-
ing statistical heterogeneity tests because of the signifi-
cant effect that heterogeneity in inclusive studies could
have on the meta-analystic results.
Conclusions
In conclusion, this meta-analysis demonstrated that BPA
concentrations measured in urine or serum is positively
associated with T2DM risk. Furthermore, prospective
cohort studies, including carefully collected data about
the dietary sources of BPA exposure and potential con-
founding, will help clarify the role of BPA in the patho-
genesis of diabetes.
Fig. 4 Funnel plot according to sample type
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